Trial Search Results

Cycled Phototherapy

Cycled phototherapy (PT) is likely to increase survival over that with continuous PT among extremely premature infants (< 750 g BW or <27 weeks GA).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

NICHD Neonatal Research Network

Collaborator: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Stanford Investigator(s):


  • Device: Phototherapy lights


Phase 3


Inclusion Criteria:

   1. Infants is inborn

   2. Infant is ≤ 750 grams at birth and/or < 27 weeks gestation at birth by best OB

   3. Infant is 12-36 hours of age.

Exclusion Criteria:

   1. Unable to enroll infant by 36 hours of age

   2. Previous phototherapy

   3. Known hemolytic disease

   4. TSB reported as >6.0 mg/dL before 12 hours age

   5. Major anomaly

   6. Overt nonbacterial infection

   7. Infant is likely to expire soon: Limiting or withdrawal of intensive care is being
   recommended to the parents, the parents are requesting withdrawal of care, or the pH
   is < 6.80 or persistent bradycardia with hypoxemia for >2h.

Ages Eligible for Study

22 Weeks - 27 Weeks

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
M. Bethany Ball